What this pack is
CYTOMEL is the brand name in this record; liothyronine sodium is the generic name. Read both together with the dosage form (oral tablet).
PACK CHECK · MARKET FIRST
CYTOMELGeneric nameliothyronine sodium
How this medicine works
The label says T3 and T4 enter the cell nucleus and bind thyroid-receptor proteins attached to DNA. The nuclear-receptor complex regulates gene transcription, messenger RNA and cytoplasmic protein synthesis. Physiologic thyroid-hormone actions are produced predominantly by T3, but mechanism cannot replace diagnosis, laboratory interpretation or an individual treatment decision.
Read source: United States ↗Current regulatory record · reviewed 2026-09-06More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- International brand name
- CYTOMEL
- Generic name
- liothyronine sodium
- Dosage-form class
- Immediate-release oral tablets at 5, 25 and 50 mcg; mcg means micrograms and 1 mg equals 1,000 mcg. The site does not perform individual conversions between micrograms and milligrams, liothyronine and levothyroxine, or different thyroid preparations.
- Route
- Oral
- Package-image status
- A source-linked public label image is available below
No source-verifiable mainland-China trade-name cue has been established for this record. This does not establish whether the medicine exists, is approved or is available in mainland China. Check pack text and current CDE/NMPA records item by item.
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
Package strength is not an individual dose. These fields help identify the exact labelled product; they do not calculate how much, how often, a missed-use action, splitting, switching or conversion.
How to read a score line: ‘scored’ or ‘unscored’ first identifies this labelled presentation. A score line by itself does not permit self-splitting, reducing or changing the product. Only an explicit statement in the current label for this exact presentation, checked with a pharmacist against the prescription, can support any further handling.
3 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
United States label · Current U.S. DailyMed brand label (SPL v15; effective 18 May 2026; prescribing information revised Apr 2025)
Equivalent to liothyronine 5 mcg per tablet; 100-tablet bottle
- Product code
- NDC 60793-115-01
- Form and route
- CYTOMEL liothyronine sodium oral tablet · oral (exact product-identity field)
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-09-06; actual marketing, stock and availability are not established.
- liothyronine (supplied as liothyronine sodium)
- 5 mcglabelled amount per tablet; not an individual tablet count, frequency, conversion or missed-use instruction
- Package
- 100 tablets per bottle
- Labelled appearance
- white to off-white · round, approximately 6 mm, unscored · imprint KPI;115Unscored in this labelled presentation
United States label · Current U.S. DailyMed brand label (SPL v15; effective 18 May 2026; prescribing information revised Apr 2025)
Equivalent to liothyronine 25 mcg per tablet; 100-tablet bottle
- Product code
- NDC 60793-116-01
- Form and route
- CYTOMEL liothyronine sodium oral tablet · oral (exact product-identity field)
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-09-06; actual marketing, stock and availability are not established.
- liothyronine (supplied as liothyronine sodium)
- 25 mcglabelled amount per tablet; not an individual tablet count, frequency, conversion or missed-use instruction
- Package
- 100 tablets per bottle
- Labelled appearance
- white to off-white · round, approximately 7 mm, scored · imprint KPI;116Scored appearance; this is not a self-splitting instruction
United States label · Current U.S. DailyMed brand label (SPL v15; effective 18 May 2026; prescribing information revised Apr 2025)
Equivalent to liothyronine 50 mcg per tablet; 100-tablet bottle
- Product code
- NDC 60793-117-01
- Form and route
- CYTOMEL liothyronine sodium oral tablet · oral (exact product-identity field)
- Container
- bottle
- Listing review
- Current label display and NDC Directory listing reviewed 2026-09-06; actual marketing, stock and availability are not established.
- liothyronine (supplied as liothyronine sodium)
- 50 mcglabelled amount per tablet; not an individual tablet count, frequency, conversion or missed-use instruction
- Package
- 100 tablets per bottle
- Labelled appearance
- white to off-white · round, approximately 8 mm, scored · imprint KPI;117Scored appearance; this is not a self-splitting instruction
PUBLIC LABEL IMAGE
Appearance and package-text clues
This current public-label package panel helps check the brand, generic name, strength and dosage-form clues only. It does not authenticate a product in hand or establish originator status, availability, sale eligibility, another package or another market.
Open the public label source ↗LABEL READING · NOT A PRESCRIPTION
CYTOMEL enlarged label: start with mcg, then review cardiac, bone, glucose and interaction risks
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
The current label prioritises microgram strengths, cardiovascular risk in older adults, hyperthyroid effects of overtreatment, bone density, diabetes control, anticoagulants and multiple interactions. The page helps bring the pack and questions to a professional; it does not calculate an individual dose, tablet count, split, switch or monitoring plan.
- The 5, 25 and 50 mcg figures are liothyronine equivalents per tablet. Mcg means micrograms, mg means milligrams, and 1 mg equals 1,000 mcg. Never detach a pack number from its unit, read 25 mcg as 25 mg or use it to calculate a tablet count.
- The 25 and 50 mcg tablets are scored; the 5 mcg tablet is unscored. This site does not treat a score as permission to self-split. Ask a pharmacist about the exact product, prescription, dose accuracy, uniformity and storage before splitting.
- Thyroid-hormone overtreatment may increase heart rate and precipitate angina or arrhythmias. Risk is higher in older adults and people with cardiovascular disease, and the label specifically notes atrial fibrillation. Chest pain, marked palpitations, fainting, breathing difficulty or acute confusion requires prompt local care and emergency help when severe; do not self-stop, switch or catch up.
- CYTOMEL carries a boxed warning: it is not for treatment of obesity or for weight loss. Doses beyond physiologic requirements can cause serious or life-threatening toxicity; do not self-combine it with weight-loss drugs, stimulants or other thyroid hormones.
- The label describes interactions involving oral anticoagulants, including warfarin-type monitoring situations, digitalis glycosides, diabetes therapy, tricyclic antidepressants, bile-acid sequestrants/ion-exchange resins, rifampin, phenobarbital, amiodarone and others. Ask a pharmacist to review the complete list and relevant monitoring; do not self-separate, increase, reduce or stop medicines from the page.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkU.S. National Library of Medicine DailyMed · United States · Public medicine label · 2026-09-06
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- United States · 2
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeDailyMed (NLM): current U.S. CYTOMEL liothyronine sodium tablet brand label (SPL v15; effective 18 May 2026) ↗Current regulatory record · reviewed 2026-09-06
Other official market or version documents for this record
These are separately reviewed product documents for the same dossier. Their market, date, dosage form and document status must stay attached to each link; they do not establish interchangeability between products, strengths, packs, indications or countries.
- FDA · United States · Regulatory product record or label archive · 2026-09-02FDA Orange Book 46th Edition (2026): CYTOMEL NDA 010379, 5/25/50 mcg and RLD/RS identities ↗Current regulatory record · reviewed 2026-09-02
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about CYTOMEL (liothyronine sodium). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
CYTOMEL is the brand in this record and liothyronine sodium is the active-ingredient name. Check both with the dosage form (Immediate-release oral tablets at 5, 25 and 50 mcg; mcg means micrograms and 1 mg equals 1,000 mcg. The site does not perform individual conversions between micrograms and milligrams, liothyronine and levothyroxine, or different thyroid preparations.) and the market on the actual pack.
Read the labelled strength in context
mg, mcg, mg/mL or a percentage describes the labelled amount in one tablet, capsule, measured volume, spray or other unit. It is not an answer to how many units a person should take.
Check before splitting or opening
Before splitting, crushing, chewing or opening anything, find an explicit instruction for this exact product in its current label and ask a pharmacist. A score line or a previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
MARKET DOCUMENTS · READ SEPARATELY
Enlarged market leaflets and regulator documents
Each link retains its own market, date, dosage form and document status. These documents support larger-print reading and item-by-item checking; they do not make products, strengths, packs, indications or use between countries or regions interchangeable.
- DailyMed (NLM): current U.S. CYTOMEL liothyronine sodium tablet brand label (SPL v15; effective 18 May 2026) ↗Current regulatory record · reviewed 2026-09-06
- FDA Orange Book 46th Edition (2026): CYTOMEL NDA 010379, 5/25/50 mcg and RLD/RS identities ↗Current regulatory record · reviewed 2026-09-02
HOW IT WORKS · NOT A TREATMENT PLAN
How liothyronine works: T3 enters the cell nucleus and regulates gene transcription and protein synthesis
- Liothyronine is T3 and levothyroxine is T4. Belonging to the thyroid-hormone family does not make them one medicine or allow self-conversion, combination, alternation or substitution using figures such as 5, 25, 50, 75 or 100.
- A relatively rapid onset and residual effects of another thyroid preparation do not create a self-switch timetable. If SYNTHROID, EUTHYROX, CYTOMEL, desiccated thyroid or another product appears on the list, first review the exact ingredient, unit, prescription and laboratory plan.
- The current label does not make whole-genome screening a routine prerequisite for everyone before CYTOMEL. Cardiovascular status, age, pregnancy, diabetes, adrenal function, interactions, symptoms and laboratory results require interpretation for the actual question and cannot be replaced by genomic testing.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- DailyMed (NLM): current U.S. CYTOMEL liothyronine sodium tablet brand label (SPL v15; effective 18 May 2026) ↗Current regulatory record · reviewed 2026-09-06
- FDA: CYTOMEL NDA 010379/S-057 supplemental approval letter (2019) ↗reviewed 2026-09-06
- FDA Orange Book 46th Edition (2026): CYTOMEL NDA 010379, 5/25/50 mcg and RLD/RS identities ↗Current regulatory record · reviewed 2026-09-02
SOURCE-TRACEABLE ARCHIVE
CYTOMELliothyronine sodium
This page includes an exact current U.S. public-label package panel for CYTOMEL, alongside documentary primary-source material. It helps check product identity, but does not itself establish originator status, product quality, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
Initial U.S. approval of CYTOMEL
All three current DailyMed product tables list NDA 010379 and a marketing start date of 8 May 1956; the Orange Book connects CYTOMEL to the same NDA.
DailyMed (NLM): current U.S. CYTOMEL liothyronine sodium tablet brand label (SPL v15; effective 18 May 2026) ↗FDA approved the S-057 labelling supplement
The approval letter describes revisions to How Supplied to resolve discrepancies between prescribing information and DailyMed, plus other editorial changes.
FDA: CYTOMEL NDA 010379/S-057 supplemental approval letter (2019) ↗Current DailyMed SPL v15 became effective
The current record retains three brand bottles at 5, 25 and 50 mcg and prescribing information revised Apr 2025.
DailyMed (NLM): current U.S. CYTOMEL liothyronine sodium tablet brand label (SPL v15; effective 18 May 2026) ↗
MARKET SCOPE
Market-record boundary
United States
Current brand label present; NDA/RLD identity verifiedAll three NDCs and package panels come from one current DailyMed label. Market availability and stock still require real-time confirmation from an authorised channel.
Mainland China and other markets
Exact market-product records not yet establishedNo local approval, trade name, pack, supply, originator/generic relationship or interchangeability is inferred from the U.S. CYTOMEL name, NDA, NDC or appearance.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
Keep international and mainland China records separate
This page has a U.S. public history/regulatory archive but no mainland China record for this specific product. That does not establish whether the medicine exists, is approved or is available in mainland China. Verify product identity, dosage form, strength, holder and the current label item by item.
RECORD FAQ
Record questions
Is 25 mcg the same as 25 mg?
No. 25 mcg is 25 micrograms, equal to 0.025 mg; the units differ by a factor of 1,000. Read the number together with mcg/μg/mg and do not calculate your own tablet count.
Can a scored 25 or 50 mcg tablet be self-split?
A score is first a product appearance and structure feature, not online permission to split. Ask a pharmacist whether the exact product can be divided and how dose accuracy and storage would be managed.
Can CYTOMEL be self-converted or combined with SYNTHROID/EUTHYROX?
No. CYTOMEL is T3, while SYNTHROID/EUTHYROX are T4 products. Formulation, pharmacokinetics, units, interactions and monitoring differ. A professional with the history, complete list and laboratory results must decide any switch or combination.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.